Literature DB >> 33762098

How old is too old for a transplant?

Daniel Weisdorf1.   

Abstract

Allogeneic transplantation remains the most definitive curative option for patients with acute myeloid leukemia (AML). However, given the median age of diagnosis of AML in the late 60s, patients and clinicians have been reluctant to offer transplant to many in the older population. In this age group, AML presents with higher risk molecular and cytogenetic phenotype and patients' comorbidities, performance status, frailty and life views all impact the decision-making about whether to proceed with transplantation. Recent analyses suggest promising outcomes and thus acknowledgement of chronological age should be tempered with assessments of performance status, frailty, donor availability and careful balancing of a patient's wishes, life goals and understanding of the risks before restricting access of older patients to the curative potential of allotransplantation.
Copyright © 2021 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Age; Allogeneic transplant; Frailty; Non-relapse mortality

Mesh:

Year:  2021        PMID: 33762098      PMCID: PMC7994544          DOI: 10.1016/j.beha.2021.101243

Source DB:  PubMed          Journal:  Best Pract Res Clin Haematol        ISSN: 1521-6926            Impact factor:   3.020


  25 in total

1.  Survival for older patients with acute myeloid leukemia: a population-based study.

Authors:  Betul Oran; Daniel J Weisdorf
Journal:  Haematologica       Date:  2012-07-06       Impact factor: 9.941

2.  Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome.

Authors:  Brian L McClune; Daniel J Weisdorf; Tanya L Pedersen; Gisela Tunes da Silva; Martin S Tallman; Jorge Sierra; John Dipersio; Armand Keating; Robert P Gale; Biju George; Vikas Gupta; Theresa Hahn; Luis Isola; Madan Jagasia; Hillard Lazarus; David Marks; Richard Maziarz; Edmund K Waller; Chris Bredeson; Sergio Giralt
Journal:  J Clin Oncol       Date:  2010-03-08       Impact factor: 44.544

3.  Improved survival of men 50 to 75 years old with acute myeloid leukemia over a 20-year period.

Authors:  Gunnar Juliusson; Oskar Hagberg; Vladimir Lj Lazarevic; Emma Ölander; Petar Antunovic; Jörg Cammenga; Lovisa Wennström; Lars Möllgård; Mats Brune; Martin Jädersten; Stefan Deneberg; Sören Lehmann; Åsa Rangert Derolf; Martin Höglund
Journal:  Blood       Date:  2019-10-31       Impact factor: 22.113

4.  Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies.

Authors:  Mohamed L Sorror; Brenda M Sandmaier; Barry E Storer; Georg N Franke; Ginna G Laport; Thomas R Chauncey; Edward Agura; Richard T Maziarz; Amelia Langston; Parameswaran Hari; Michael A Pulsipher; Wolfgang Bethge; Firoozeh Sahebi; Benedetto Bruno; Michael B Maris; Andrew Yeager; Finn Bo Petersen; Lars Vindeløv; Peter A McSweeney; Kai Hübel; Marco Mielcarek; George E Georges; Dietger Niederwieser; Karl G Blume; David G Maloney; Rainer Storb
Journal:  JAMA       Date:  2011-11-02       Impact factor: 56.272

5.  Myeloablative allogeneic hematopoietic stem cell transplantation in elderly patients.

Authors:  M Ditschkowski; A H Elmaagacli; R Trenschel; N K Steckel; M Koldehoff; D W Beelen
Journal:  Clin Transplant       Date:  2006 Jan-Feb       Impact factor: 2.863

6.  Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia.

Authors:  Courtney D DiNardo; Keith Pratz; Vinod Pullarkat; Brian A Jonas; Martha Arellano; Pamela S Becker; Olga Frankfurt; Marina Konopleva; Andrew H Wei; Hagop M Kantarjian; Tu Xu; Wan-Jen Hong; Brenda Chyla; Jalaja Potluri; Daniel A Pollyea; Anthony Letai
Journal:  Blood       Date:  2018-10-25       Impact factor: 22.113

7.  Allotransplantation for patients age ≥40 years with non-Hodgkin lymphoma: encouraging progression-free survival.

Authors:  Brian L McClune; Kwang Woo Ahn; Hai-Lin Wang; Joseph H Antin; Andrew S Artz; Jean-Yves Cahn; Abhinav Deol; César O Freytes; Mehdi Hamadani; Leona A Holmberg; Madan H Jagasia; Ann A Jakubowski; Mohamed A Kharfan-Dabaja; Hillard M Lazarus; Alan M Miller; Richard Olsson; Tanya L Pedersen; Joseph Pidala; Michael A Pulsipher; Jacob M Rowe; Wael Saber; Koen W van Besien; Edmund K Waller; Mahmoud D Aljurf; Görgun Akpek; Ulrike Bacher; Nelson J Chao; Yi-Bin Chen; Brenda W Cooper; Jason Dehn; Marcos J de Lima; Jack W Hsu; Ian D Lewis; David I Marks; Joseph McGuirk; Mitchell S Cairo; Harry C Schouten; Jeffrey Szer; Muthalagu Ramanathan; Bipin N Savani; Matthew Seftel; Gérard Socie; Ravi Vij; Erica D Warlick; Daniel J Weisdorf
Journal:  Biol Blood Marrow Transplant       Date:  2014-03-15       Impact factor: 5.742

8.  Allogeneic hematopoietic cell transplantation compared to chemotherapy consolidation in older acute myeloid leukemia (AML) patients 60-75 years in first complete remission (CR1): an alliance (A151509), SWOG, ECOG-ACRIN, and CIBMTR study.

Authors:  Celalettin Ustun; Jennifer Le-Rademacher; Hai-Lin Wang; Megan Othus; Zhuoxin Sun; Brittny Major; Mei-Jie Zhang; Elizabeth Storrick; Jacqueline M Lafky; Selina Chow; Krzysztof Mrózek; Eyal C Attar; Such Nand; Clara D Bloomfield; Larry D Cripe; Martin S Tallman; Frederick Appelbaum; Richard A Larson; Guido Marcucci; Gail J Roboz; Geoffrey L Uy; Richard M Stone; Aminah Jatoi; Thomas C Shea; Marcos de Lima; James M Foran; Brenda M Sandmaier; Mark R Litzow; Harry P Erba; Arti Hurria; Daniel J Weisdorf; Andrew S Artz
Journal:  Leukemia       Date:  2019-05-09       Impact factor: 11.528

9.  Barriers to Hematopoietic Cell Transplantation for Adults in the United States: A Systematic Review with a Focus on Age.

Authors:  Colin Flannelly; Bryan E-Xin Tan; Jian Liang Tan; Colin M McHugh; Chandrika Sanapala; Tara Lagu; Jane L Liesveld; Omar Aljitawi; Michael W Becker; Jason H Mendler; Heidi D Klepin; Wendy Stock; Tanya M Wildes; Andrew Artz; Navneet S Majhail; Kah Poh Loh
Journal:  Biol Blood Marrow Transplant       Date:  2020-09-20       Impact factor: 5.609

10.  Development and Validation of a Novel Acute Myeloid Leukemia-Composite Model to Estimate Risks of Mortality.

Authors:  Mohamed L Sorror; Barry E Storer; Amir T Fathi; Aaron T Gerds; Bruno C Medeiros; Paul Shami; Andrew M Brunner; Mikkael A Sekeres; Sudipto Mukherjee; Esteban Peña; Mahmoud Elsawy; Shylo Wardyn; Jennifer Whitten; Rachelle Moore; Pamela S Becker; Jeannine S McCune; Frederick R Appelbaum; Elihu H Estey
Journal:  JAMA Oncol       Date:  2017-12-01       Impact factor: 31.777

View more
  1 in total

Review 1.  Pitfalls and Successes in Trials in Older Transplant Patients with Hematologic Malignancies.

Authors:  Aaron T Zhao; Anthony D Sung
Journal:  Curr Oncol Rep       Date:  2022-01-21       Impact factor: 5.075

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.